Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/17371
Efficacy of Anakinra in Refractory Adult-Onset Still's Disease Multicenter Study of 41 Patients and Literature Review
Identifiers
ISSN: 0025-7974
eISSN: 1536-5964
WOS ID: 000369534600021
Scopus EID: 2-s2.0-84943195545
PMID: 26426623
Embase PUI: L606280314
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Ortiz-Sanjuan, Francisco; Blanco, Ricardo; Riancho-Zarrabeitia, Leyre; Castaneda, Santos; Olive, Alejandro; Riveros, Anne; Velloso-Feijoo, Maria L.; Narvaez, Javier; Jimenez-Moleon, Inmaculada; Maiz-Alonso, Olga; Ordonez, Carmen; Bernal, Jose A.; Hernandez, Maria V.; Sifuentes-Giraldo, Walter A.; Gomez-Arango, Catalina; Galindez-Agirregoikoa, Eva; Blanco-Madrigal, Juan; Ortiz-Santamaria, Vera; del Blanco-Barnusell, Jordi; De Dios, Juan R.; Moreno, Mireia; Fiter, Jordi; de los Riscos, Marina; Carreira, Patricia; Rodriguez-Valls, Maria J.; Gonzalez-Vela, M. Carmen; Calvo-Rio, Vanesa; Loricera, Javier; Palmou-Fontana, Natalia; Pina, Trinitario; Llorca, Javier; Gonzalez-Gay, Miguel A.Publication date
2015-09Document type
research articleCitation
Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L, Castaneda S, Olive A, Riveros A, et al. Efficacy of Anakinra in Refractory Adult-Onset Still's Disease Multicenter Study of 41 Patients and Literature Review. Medicine (Baltimore). 2015 Sep;94(39):e1554.Abstract
Adult-onset Still's disease (AOSD) is often refractory to standard therapy. Anakinra (ANK), an interleukin-1 receptor antagonist, has demonstrated efficacy in single cases and small series of AOSD. We assessed the efficacy of ANK in a series of AOSD patients.Multicenter retrospective open-label study. ANK was used due to lack of efficacy to standard synthetic immunosuppressive drugs and in some cases also to at least 1 biologic agent.Forty-one patients (26women/15 men) were recruited. They had a mean age of 34.414 years and a median [interquartile range (IQR)] AOSD duration of 3.5 [2-6] years before ANK onset. At that time the most common clinical features were joint manifestations 87.8%, fever 78%, and cutaneous rash 58.5%. ANK yielded rapid and maintained clinical and laboratory improvement. After 1 year of therapy, the frequency of joint and cutaneous manifestations had decreased to 41.5% and to 7.3% respectively, fever from 78% to 14.6%, anemia from 56.1% to 9.8%, and lymphadenopathy from 26.8% to 4.9%. A dramatic improvement of laboratory parameters was also achieved. The median [IQR] prednisone dose was also reduced from 20 [11.3-47.5] mg/day at ANK onset to 5 [0-10] at 12 months. After a median [IQR] follow-up of 16 [5-50] months, the most important side effects were cutaneous manifestations (n=8), mild leukopenia (n=3), myopathy (n=1), and infections (n=5).ANK is associated with rapid and maintained clinical and laboratory improvement, even in nonresponders to other biologic agents. However, joint manifestations are more refractory than the systemic manifestations.
Publisher version
https://dx.doi.org/10.1097/MD.0000000000001554MeSH
Immunosuppressive AgentsInterleukin 1 Receptor Antagonist Protein
Male
Adult
Female
Humans
Drug Therapy, Combination
Prednisone
Middle Aged
Retrospective Studies
DeCS
Quimioterapia CombinadaHumanos
Persona de Mediana Edad
Femenino
Inmunosupresores
Proteína Antagonista del Receptor de Interleucina 1
Estudios Retrospectivos
Adulto
Prednisona
Masculino